This study is testing new treatments for a type of breast cancer where hormones help the cancer grow. It's called "HR+/HER2- breast cancer." "HR+" means hormone receptor-positive, and "HER2-" means human epidermal growth factor receptor 2 negative. This trial compares a combination of medicines: gedatolisib and fulvestrant, sometimes with another medicine called palbociclib, against standard treatment options. Gedatolisib blocks signals that help cancer grow, and fulvestrant stops estrogen from attaching to cancer cells. Palbociclib stops cancer cells from dividing.

Key Points:

• This study will need participants whose cancer has not responded to certain previous treatments.
• Participants will be randomly assigned to different treatment groups based on their cancer gene type.
• Participation involves regular check-ups and tests to monitor treatment effects and side effects.

People cannot join if they have certain health issues, like uncontrolled diabetes or specific heart problems. Women must not be pregnant or breastfeeding. If you join, you cannot participate in other drug trials at the same time. The goal is to find out if these new combinations work better than current treatments. It's important to consider the study's requirements and potential risks before joining.